Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction

Wu, Tao; Li, Peiling; Sun, D Z

doi:10.1166/jnn.2020.18875

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7][8] While some studies support the use of rtPA, there are concerns about the quality and reliability of the evidence, particularly regarding the time window, dosage, and treatment outcomes of rtPA. [9][10][11][12][13] The inconsistency in clinical effects is a significant issue. This variation in outcomes can be attributed to several factors, such as patient selection criteria, treatment strategies, and potential risks, including the risk of increased bleeding.…”

Section: Introductionmentioning

confidence: 99%

Impact of Early Mobilization on Patients With Acute Ischemic Stroke Treated With Thrombolysis or Thrombectomy: A Randomized Controlled Trial

Yen,

Pan,

Jeng

et al. 2024

Neurorehabil Neural Repair

View full text Add to dashboard Cite

Background Early mobilization (EM) within 24 to 72 hours post-stroke may improve patients’ performance and ability. However, after intravenous thrombolysis (IVT) or mechanical thrombectomy (MT), the increased risk of hemorrhagic complications impacts the implementation of early out-of-bed mobilization. Few studies have investigated EM after IVT or MT for acute ischemic stroke (AIS), and its impact in these patients is unknown. Objective To investigate the effect of EM on AIS treated with IVT or MT.| Methods We recruited 122 patients with first AIS; 60 patients were treated with IVT, and 62 patients were treated with MT. For each IVT and MT cohort, the control groups received standard early rehabilitation, and the intervention groups received an EM protocol. The training lasted 30 minutes/day, 5 days/week until discharge. Main Outcomes Measures The effectiveness of the interventions was evaluated using the motor domain of the Functional Independence Measure (FIM-motor) and the Postural Assessment Scale for Stroke Patients (PASS) at baseline, 2-week, 4-week, and 3-month post-stroke, the Functional Ambulation Category 2-week post-stroke, and the total length of stay at the stroke center. Results Both IVT and MT treatment groups showed improved FIM-motor and PASS scores over time; however, only the IVT EM group had significantly improved FIM-motor performance within 1 month after stroke than the control group. Conclusion. An EM protocol with the same intervention time and session frequency per day as in the standard care protocol was effective in improving the functional ability of stroke patients after IVT.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of Early Mobilization on Patients With Acute Ischemic Stroke Treated With Thrombolysis or Thrombectomy: A Randomized Controlled Trial

Yen,

Pan,

Jeng

et al. 2024

Neurorehabil Neural Repair

View full text Add to dashboard Cite

show abstract

“…At present, antiplatelet drugs such as aspirin, ozagrel, and clopidogrel are mostly used in clinic, but the efficacy remains unsatisfactory [6]. Edaravone, a free radical scavenger, can improve the local blood flow of cerebral infarction lesions, prevent the disease progression, and alleviate neurological symptoms, with confirmed efficacy in diseases such as acute carbon monoxide poisoning, cardiogenic cerebral infarction, and hypertensive cerebral hemorrhage [7][8][9]. Although not recommended in the guidelines, anticoagulant therapy for ACI is very common in foreign countries, with the common anticoagulant drugs such as aspirin, warfarin, and plavix.…”

Section: Introductionmentioning

confidence: 99%

Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-α Levels and Activity of Daily Living in Patients with Acute Cerebral Infarction

Sun

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. To explore the effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-α levels and the activity of daily living (ADL) in patients with acute cerebral infarction (ACI). Methods. The clinical data of 84 ACI patients treated in our hospital from August 2020 to August 2021 were retrospectively analyzed, and they were divided into the routine group (n = 42) and the combined group (n = 42) according to the order of admission. Both groups were treated with routine clinical treatment, and the combined group was additionally treated with edaravone combined with anticoagulant therapy. Serum samples were collected from both groups after treatment. ELISA was used to detect the serum inflammatory factor levels, and the modified Barthel index score was used to evaluate the ADL of patients. Results. Compared with the routine group, the combined group achieved obviously lower levels of PMA, CD62p, and serum inflammatory factors after treatment ( P < 0.001 ), higher modified Barthel score after treatment ( P < 0.001 ), lower plasma viscosity, platelet aggregation rate, and plasma fibrinogen level after treatment ( P < 0.001 ), and higher clinical overall efficacy ( P < 0.05 ). Conclusion. Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients. This strategy greatly reduces the platelet-activating factor levels of patients and improves the comprehensive clinical efficacy, and its further research will help to establish a better solution for these patients.

show abstract

“…The human tissue-type plasminogen activator(tPA) is a serine protease synthesized and secreted by vascular endothelial cells, which can efficiently and specifically dissolve thrombus and it is a good second-generation thrombolytic drug [4][5] . The recombinant human plasminogen activator (rhPA) in this study is a recombinant mutants of natural tPA [6] , which belongs to the third generation thrombolytic drugs and has more superior thrombolytic efficacy than natural tPA. Therefore, the study of how to stably improve the rhPA expression level is an important guideline for the development of new thrombolytic drugs.…”

Section: Introductionmentioning

confidence: 99%

The High-Level Expression Analysis of RhPA In The RhPA/gGH Double-Transgenic Rabbits And Its Thrombolysis Activity In Vitro

Song

Luo

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: In this study, the rhPA/gGH double transgenic rabbits were constructed, and the expression level of rhPA,rabbit growth and development features were analyzed, which might provide a new idea for obtain rhPA high level expression transgenic animals.Method: Two rhPA transgenic rabbits fertilized eggs were microinjected with linearized GH plasmid to obtain the rhPA/gGH rabbits.The integration of rhPA/gGH gene was detected by PCR. The rhPA expression level in transgenic rabbit milk was detected by ELISA and Western blotting,and FAPA was performed to detect the in vitro thrombolytic activity of rhPA.The body weight of transgenic rabbits at different growth stages were measured to test the effect of gGH gene on rhPA/gGH double transgenic rabbits growth and development .Result: A total of 151 rhPA transgenic rabbits fertilized eggs were obtained through superovulation, 125 of them were microinjected with linearized GH plasmid and transplanted into 8 surrogate mother rabbits.Six surrogate mother rabbits were pregnant, with a pregnancy rate of 75.0% (6/8)，16 rhPA/gGH gene double transgenic rabbits were identified by PCR (10♂,6♀). The rhPA expression levels in rhPA single-transgenic rabbit whey were 0.27–0.63g/L, while the rhPA expression leves were 4.98-12.24 g/L in the rhPA/gGH double-transgenic rabbits whey. The rhPA expression levels of rhPA/gGH double-transgenic rabbit whey were significantly increased by about 17.2–23.8 times, and had higher thrombolytic activity in vitro. There was no significant difference in body weight between rhPA/gGH double transgenic rabbits, rhPA single transgenic or non-transgenic rabbits from birthday to 10 months age(P>0.05). Conclusion: The rhPA/gGH double transgenic rabbits were successfully constrected, which was proved that the introduction of gGH gene could significantly increase the rhPA expression level in the milk of transgenic rabbits and without affecting the growth and development of transgenic rabbits, which laid a foundation for the preparation of transgenic rabbits with higher recombinant protein expression level in the future, and also provide new ideas and new methods for the establishment of mammary gland bioreactor.

show abstract

Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction

Cited by 6 publications

References 0 publications

Impact of Early Mobilization on Patients With Acute Ischemic Stroke Treated With Thrombolysis or Thrombectomy: A Randomized Controlled Trial

Impact of Early Mobilization on Patients With Acute Ischemic Stroke Treated With Thrombolysis or Thrombectomy: A Randomized Controlled Trial

Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-α Levels and Activity of Daily Living in Patients with Acute Cerebral Infarction

The High-Level Expression Analysis of RhPA In The RhPA/gGH Double-Transgenic Rabbits And Its Thrombolysis Activity In Vitro

Contact Info

Product

Resources

About